The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by covered entities against drug manufacturers for denying 340B discounts on drug dispensed by contract pharmacies.
In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies
